Full-Time

Manufacturing Manager

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

Compensation Overview

$125k - $150k/yr

San Diego, CA, USA

In Person

On-site in San Diego; occasional travel to other San Diego facilities as needed.

Bachelor's

Category
Manufacturing & Production Operations

Get referred to Abzena

See people who can refer or advise you

Requirements
  • Bachelor's degree in Biotechnology, Biochemical Engineering, Chemical Engineering, Biology, Life Sciences, or related discipline.
  • 8+ years of experience in biopharmaceutical or biologics manufacturing within a regulated cGMP environment.
  • 3+ years of direct people leadership experience.
  • Strong understanding of biologics manufacturing processes, including upstream and downstream operations.
  • Experience supporting clinical and/or commercial biologics manufacturing.
  • Thorough knowledge of cGMP regulations, quality systems, and regulatory expectations.
  • Demonstrated success leading teams in a fast-paced manufacturing environment.
  • Strong problem-solving, organizational, communication, and leadership skills.
  • Travel between Abzena sites (local San Diego CA facilities) as needed.
Responsibilities
  • Manufacturing Operations Leadership: Manage day-to-day manufacturing activities for upstream, downstream, and process support operations.
  • Ensure production campaigns are executed safely, efficiently, and in accordance with approved batch records and cGMP requirements.
  • Coordinate manufacturing schedules to meet client and business commitments.
  • Monitor production performance metrics and implement corrective actions as needed.
  • Lead manufacturing readiness activities for technology transfers, process validation, and commercial production.
  • Quality and Compliance: Identify, assess, and mitigate risks to ensure the safety, purity, quality, and effectiveness of manufactured products, developing contingencies to address potential challenges.
  • Develop a successful team, building technical and leadership capabilities to meet current and future business needs.
  • Ensure controlled documents for the area of responsibility are maintained, with active owners assigned for periodic reviews.
  • Alert senior management of significant quality, compliance, supply, and safety risks.
  • Accountable for the functional key performance indicators and evaluations for Management Reviews.
  • Plan and oversee GMP activities for assigned areas through downstream levels of management.
  • Support and drive Continuous Improvement initiatives, programs, and projects.
  • Serve as the subject matter expert for the functional area during health authority inspections.
  • Ensure the right people and resources are in place and optimally allocated to achieve results.
  • Project Management: Collaborate with the MSAT team to transfer processes and technologies into manufacturing, ensuring a smooth transition by identifying potential risk and developing mitigation strategies.
  • Lead and manage manufacturing projects from inception through completion, ensuring alignment with business objectives, timelines and quality standards.
  • Ensure effective decision-making and clear, timely communication across the organization.
  • Safety & Training: Promote and maintain a culture of safety, ensuring adherence to all safety protocols.
  • Ensure ongoing training and development of manufacturing staff on new technologies, SOPs and regulatory guidelines.
  • Demonstrate personal credibility and build strong working relationships across organizational and geographical boundaries.
  • Ensure an adequate number of personnel with appropriate education, experience, and training in accordance with cGMP requirements
  • Foster an environment that encourages accountability, innovation, continuous improvement, learning, and knowledge-sharing.

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Get referred to Abzena

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 2025 CEO Geoffrey Glass unified strategy after chairman tenure.
  • September 2025 GS knockout launches expand standalone and GMP cell-line revenue.
  • 2026 Tasrif and Promatix projects show customer demand for Abzena platforms.

What critics are saying

  • Lonza, WuXi, and Samsung Biologics outscale Abzena on global capacity.
  • Abzena's 2025 class-action settlement keeps employment claims visible to candidates.
  • If ADC and AOC programs slow, expanded CDMO capacity sits underutilized.

What makes Abzena unique

  • Abzena owns integrated discovery-to-GMP workflows for complex biologics and bioconjugates.
  • ThioBridge and AbZelectPRO KO platforms speed ADC and afucosylated protein programs.
  • Frost & Sullivan named Abzena a 2026 leader for ADC CDMOs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Abzena
Jul 15th, 2026
Outsourced Pharma capability Update - Cell Line Development June 2026.

Outsourced Pharma capability Update - Cell Line Development June 2026. Early cell line decisions define everything that comes after: yield, stability, manufacturability, and timelines. That's why Abzena PLC presented at the Outsourced Pharma Capabilities Update on June 16th, which is focused on Cell Line Development strategies. Abzena's VP & Scientific Leader of Cell Line Development, John E. Gill IV, presented a talk on "Integrated Cell Line Development: Manufacturability to GMP-Ready by Design." John broke down how a truly integrated approach, one built with GMP readiness and manufacturability in mind from day one, changes the trajectory of complex biologic programs. The result: - Accelerated timelines to GMP - Reduced downstream risk - Cell lines engineered to meet GMP standards, not retrofitted to them - A smoother, faster path from discovery to clinical & commercial manufacturing When GMP readiness is designed in from the start, not added later, programs don't stall. They move forward faster.

Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth